Telix Pharmaceuticals Limited (ASX:TLX)
13.74
+0.04 (0.29%)
At close: Dec 12, 2025
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $390.36M USD in the half year ending June 30, 2025, with 165.59% growth. This brings the company's revenue in the last twelve months to $664.23M, up 55.35% year-over-year. In the year 2024, Telix Pharmaceuticals had annual revenue of $484.69M with 41.49% growth.
Revenue (ttm)
$664.23M
Revenue Growth
+55.35%
P/S Ratio
4.59
Revenue / Employee
$2.84M
Employees
234
Market Cap
4.65B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 484.69M | 142.12M | 41.49% |
| Dec 31, 2023 | 342.57M | 233.76M | 214.82% |
| Dec 31, 2022 | 108.81M | 103.29M | 1,870.12% |
| Dec 31, 2021 | 5.52M | 1.50M | 37.33% |
| Dec 31, 2020 | 4.02M | 1.57M | 64.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Ramsay Health Care | 17.79B |
| Sonic Healthcare | 9.65B |
| Ansell | 3.06B |
| Cochlear | 2.34B |
| Regis Healthcare | 1.16B |
| Neuren Pharmaceuticals | 218.86M |
| Pro Medicus | 212.98M |
Telix Pharmaceuticals News
- 1 day ago - Class Action Filed Against Telix Pharmaceuticals Ltd. (TLX) - January 9, 2026 Deadline to Join – Contact Levi & Korsinsky - GlobeNewsWire
- 1 day ago - TLX DEADLINE: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 - TLX - PRNewsWire
- 1 day ago - 21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures - GlobeNewsWire
- 1 day ago - Telix Pharmaceuticals Ltd. Class Action: Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. - PRNewsWire
- 2 days ago - 21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures - PRNewsWire
- 2 days ago - Deadline Alert: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewsWire
- 2 days ago - TELIX CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights - GlobeNewsWire
- 2 days ago - The Gross Law Firm Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 – TLX - GlobeNewsWire